Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Multifunctional Fe3O4@polyacrylic acid/Au nanoclusters/zeolitic imidazolate framework-8 nanoparticles (Fe3O4@PAA/AuNCs/ZIF-8 NPs) integrating tri-modal cancer imaging (magnetic resonance, computed X-ray tomography and fluorescence imaging) and chemotherapy into a single system were fabricated by using a facile, mild and reproducible strategy. The obtained NPs possess many merits including ultrahigh doxorubicin (DOX) loading capability (1.54 mg DOX per mg NPs), dual pH-responsive controlled drug release, tri-modal cancer imaging ability, facile magnetic separation and good biocompatibility. Importantly, the NPs exhibit low systematic toxicity and high antitumor therapy efficacy in vivo through tail vein injection. Furthermore, the achievement of in vitro tri-modal cancer cell imaging reveals the potential of Fe3O4@PAA/AuNCs/ZIF-8 NPs for cancer diagnosis and visualized-synergistic therapy. Taken together, Fe3O4@PAA/AuNCs/ZIF-8 NPs can be developed as a promising theranostic agent that combines multiple capabilities for cancer treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c5bm00186b | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!